In the United States, 1 in 6 men who have sex with men (MSM), including 1 in 2 Black, 1 in 4 Latinx and 1 in 11 white MSM, will be diagnosed with HIV in their lifetime. The numbers among transgender women (TGW) are equally concerning; with an estimate of 14% living with HIV, the majority of whom are Black or Latinx New approaches to HIV prevention, including new options for HIV pre-exposure prophylaxis (PrEP) are needed. The PURPOSE 2 Study aims to see if a twice yearly injection for HIV prevention is safe and effective.

What is the purpose of this study?

This study will test the experimental drug Lenacapavir (LEN) for the prevention of HIV infection, also known as Pre-Exposure Prophylaxis (PrEP). This study will also compare the effectiveness of LEN to Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF; Truvada), which has already been approved in several countries for use as PrEP.

INTERESTED IN LEARNING MORE ABOUT TWICE A YEAR MEDICATION FOR PrEP?

You may be eligible for a study testing an investigational injectable PrEP medication given twice a year if:

• You’re over 18 years old

• You haven’t been tested for HIV in the last 3 months

• Not currently on PrEP

• You’re having anal sex with men or transwomen partners and don’t always use condoms

CONTACT US: 323-461-3106